To include your compound in the COVID-19 Resource Center, submit it here.

Actemra regulatory update

Roche disclosed in its 4Q10 earnings that last year it submitted regulatory applications in the U.S. and EU to expand the label of tocilizumab to include the treatment of systemic juvenile idiopathic arthritis. The humanized mAb against

Read the full 375 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE